Noile-Immune Biotech Inc

Capital Structure and Liquidity Noile-Immune Biotech Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥3,918,321,000, representing 97.1% of its total assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. The current ratio of 53.54 further underscores its ability to meet short-term obligations. ### Profitability and Returns The company reported a net loss of ¥793,536,000 and an operating loss of ¥797,255,000 in the latest period. Return on equity (ROE) and return on assets (ROA) were -20.18% and -19.78%, respectively, indicating significant underperformance relative to industry norms for biotechnology firms. These metrics suggest the company is in an early-stage development phase with high R&D expenditures. ### Segments and Geographic Exposure The company operates through a single business segment, the Cancer Immunotherapy Drug Discovery Business, which focuses on gene-modified immuno-cell therapies for solid tumors. The company's operations are concentrated in Japan, with no disclosed international revenue streams. This geographic concentration may limit diversification benefits and expose the company to regional regulatory and economic risks. ### Growth Trajectory The company is in a pre-revenue phase, with total revenue at ¥5,000,000 in the latest period. Analysts have assigned a mean price target of ¥440.00, with a strong buy recommendation, indicating optimism about future growth potential. However, the company's current financial performance, characterized by significant losses, suggests that revenue growth will depend on successful clinical trials and regulatory approvals. ### Risk Factors The company faces liquidity risk due to its negative operating and free cash flows, which totaled ¥752,219,000 and ¥793,536,000, respectively. However, the risk of dilution is currently low, with no immediate filing-based flags detected. The company's valuation is not adjusted for any specific factors, and its capital structure remains undiluted. ### Recent Events Noile-Immune Biotech Inc has not disclosed any recent significant events, such as major regulatory filings or earnings transcripts, that would impact its current financial or operational status.